Atricure Inc’s recent filing unveils that its Chief Scientific Officer Doraiswamy Vinayak unloaded Company’s shares for reported $83600.0 on May 28 ’25. In the deal valued at $33.44 per share,2,500 shares were sold. As a result of this transaction, Doraiswamy Vinayak now holds 73,550 shares worth roughly $2.46 million.
Then, VINAYAK DORAISWAMY bought 2,500 shares, generating $83,600 in total proceeds.
Before that, Prange Karen sold 6,100 shares. Atricure Inc shares valued at $232,532 were divested by the Director at a price of $38.12 per share. As a result of the transaction, Prange Karen now holds 17,828 shares, worth roughly $0.6 million.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who increased its forecast for the stock in late April from “a Perform” to “an Outperform”. JMP Securities began covering ATRC with “Mkt outperform” recommendation on October 23, 2023. UBS started covering the stock on September 29, 2023. It rated ATRC as “a Buy”.
Price Performance Review of ATRC
On Tuesday, Atricure Inc [NASDAQ:ATRC] saw its stock fall -2.31% to $33.39. Over the last five days, the stock has lost -3.86%. Atricure Inc shares have risen nearly 9.26% since the year began. Nevertheless, the stocks have risen 47.87% over the past one year.
How much short interest is there in Atricure Inc?
A steep rise in short interest was recorded in Atricure Inc stocks on 2025-05-15, growing by 0.22 million shares to a total of 1.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 1.34 million shares. There was a rise of 14.03%, which implies that there is a positive sentiment for the stock.
